Maxim analyst Anthony Vendetti lowered the firm’s price target on Dermata Therapeutics (DRMA) to $3 from $6 and keeps a Buy rating on the shares. The firm notes the company’s Q1 operating expenses were below its estimates while also citing its statistically significant positive topline data from STAR-1 study, though its adjusted model reflects Dermata’s anticipated capital raise, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRMA:
- Dermata Faces Nasdaq Delisting Risk Over Bid Price
- Dermata Reports Positive Phase 3 Trial Results
- Dermata Therapeutics reports Q1 EPS (45c) vs. ($7.06) last year
- Dermata Therapeutics sees cash runway into 1Q26
- Optimistic Buy Rating for Dermata Therapeutics Driven by Promising Phase 3 Trial Results and Strong Financial Position